Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide acetate 22.5 mg depot pharmacokinetic and pharmacodynamic study in prostate cancer
2006-005964-24Phase 3Terminated
- Sponsor
- Italfarmaco
- Start
- Jan 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by Italfarmaco. Primary endpoints: Main testosterone pharmacodynamic parameters, Pharmacokinetics of leuprolide acetate depot and 1 more. Started Jan 2007; status: terminated.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-005964-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005964-24.